Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings

This article was originally published in The Pink Sheet Daily

Executive Summary

Briefing documents for the advisory committee, now delayed by snow, show that many enrollees lacked a confirmed Bcr-Abl T315I mutation.
Advertisement

Related Content

Teva’s Synribo: Salvage Therapy, But Not Personalized Medicine
Pixuvri And Omapro Will Get Tight Reviews After Rescheduled Committee Meeting
Pixuvri And Omapro Will Get Tight Reviews After Rescheduled Committee Meeting
FDA Plows Out: Telecommuting Triumphs As Blizzard Puts A Hole In CDER's Roof
FDA Plows Out: Telecommuting Triumphs As Blizzard Puts A Hole In CDER's Roof

Topics

Advertisement
UsernamePublicRestriction

Register

PS070310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel